MAYNE PHARMA GROUP LIMITED — Board/Management Information 2012

May 22, 2012

==> picture [115 x 58] intentionally omitted <==

23 May 2012

MAYNE PHARMA ANNOUNCES NEW SALES & MARKETING DIRECTOR

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that it has appointed Mr Peter Truelove as National Sales and Marketing Director. The newly created role will focus on growing Mayne Pharma’s Australian pharmaceutical business which currently generates annual sales of approximately $10 million through a number of proprietary products including Astrix®, Doryx®, Eryc® and Magnoplasm®. Going forward, the business will be focused on expanding the product offering to include new in-licensed and acquired specialty pharmaceutical products, together with expansion of existing products market share through enhanced sales and marketing strategies.

Prior to joining Mayne Pharma, Mr Truelove was the Sales and Marketing Director for Fresenius Kabi (Australia and New Zealand), a leading global provider of injectable drugs and infusion solutions. He also spent 11 years with Hospira Pty Ltd (previously Mayne Pharma Limited and F H Faulding & Co) in various national sales leadership roles, culminating in the position of Vice President, Commercial Operations, ANZ where he had responsibility for sales approaching $150 million per year.

Mayne Pharma CEO Mr Scott Richards said, “Peter will be a great addition to the Mayne Pharma team and has a proven track record of sales leadership and success in both the branded and generic segments of the Australian pharmaceutical industry. Peter has worked across multiple therapeutic areas and diverse customer channels. I look forward to accelerating the growth of our domestic own brand business with Peter’s support and leadership.”

For further information contact:

Scott Richards +61 8 8209 2410 Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com